

# Tharick Ali Pascoal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1944203/publications.pdf>

Version: 2024-02-01

132  
papers

5,017  
citations

126907

33  
h-index

110387

64  
g-index

152  
all docs

152  
docs citations

152  
times ranked

4611  
citing authors

#	ARTICLE	IF	CITATIONS
1	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> , The, 2020, 19, 422-433.	10.2	668
2	Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 25.	6.2	285
3	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. <i>Acta Neuropathologica</i> , 2021, 141, 709-724.	7.7	285
4	Microglial activation and tau propagate jointly across Braak stages. <i>Nature Medicine</i> , 2021, 27, 1592-1599.	30.7	235
5	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400.	12.8	219
6	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , 2021, 78, 1471.	9.0	204
7	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , 2021, 26, 429-442.	7.9	186
8	Association of Apolipoprotein E $\epsilon$ 4 With Medial Temporal Tau Independent of Amyloid- $\beta$ . <i>JAMA Neurology</i> , 2020, 77, 470.	9.0	154
9	18F-MK-6240 PET for early and late detection of neurofibrillary tangles. <i>Brain</i> , 2020, 143, 2818-2830.	7.6	147
10	In vivo quantification of neurofibrillary tangles with [18F]MK-6240. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 74.	6.2	120
11	Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 251.	4.8	112
12	Amyloid- $\beta$ and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease. <i>Molecular Psychiatry</i> , 2017, 22, 306-311.	7.9	105
13	Mild behavioral impairment is associated with $\beta$ -amyloid but not tau or neurodegeneration in cognitively intact elderly individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, 192-199.	0.8	102
14	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. <i>Nature Reviews Neurology</i> , 2022, 18, 400-418.	10.1	99
15	Validation of a Regression Technique for Segmentation of White Matter Hyperintensities in Alzheimer's Disease. <i>IEEE Transactions on Medical Imaging</i> , 2017, 36, 1758-1768.	8.9	85
16	Identifying incipient dementia individuals using machine learning and amyloid imaging. <i>Neurobiology of Aging</i> , 2017, 59, 80-90.	3.1	85
17	Synergistic interaction between amyloid and tau predicts the progression to dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 644-653.	0.8	79
18	VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis. <i>Frontiers in Neuroinformatics</i> , 2016, 10, 20.	2.5	73

#	ARTICLE	IF	CITATIONS
19	Biomarker modeling of Alzheimer's disease using PET-based Braak staging. <i>Nature Aging</i> , 2022, 2, 526-535.	11.6	73
20	Determining Amyloid- $\beta^2$ Positivity Using $^{18}\text{F}$ -AZD4694 PET Imaging. <i>Journal of Nuclear Medicine</i> , 2021, 62, 247-252.	5.0	65
21	Cerebrospinal fluid p-tau <sub>231</sub> as an early indicator of emerging pathology in Alzheimer's disease. <i>EBioMedicine</i> , 2022, 76, 103836.	6.1	65
22	Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. <i>Neurology</i> , 2017, 88, 1814-1821.	1.1	61
23	Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. <i>Brain</i> , 2020, 143, 3793-3804.	7.6	60
24	A $\beta^2$ -induced vulnerability propagates via the brain's default mode network. <i>Nature Communications</i> , 2019, 10, 2353.	12.8	58
25	Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 80.	6.2	55
26	Anosognosia predicts default mode network hypometabolism and clinical progression to dementia. <i>Neurology</i> , 2018, 90, e932-e939.	1.1	54
27	APOE $\epsilon^4$ potentiates the relationship between amyloid- $\beta^2$ and tau pathologies. <i>Molecular Psychiatry</i> , 2021, 26, 5977-5988.	7.9	51
28	Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid- $\beta^+$ positive individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 679-689.	2.4	48
29	Longitudinal $^{18}\text{F}$ -MK-6240 tau tangles accumulation follows Braak stages. <i>Brain</i> , 2021, 144, 3517-3528.	7.6	47
30	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 207-219.	2.3	44
31	Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2018, 7, 23.	8.0	43
32	Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE $\epsilon^4$ , and Cognitive Impairment. <i>Neurology</i> , 2021, 96, e975-e985.	1.1	42
33	Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 463-472.	1.5	41
34	A multicenter comparison of [ $^{18}\text{F}$ ]flortaucipir, [ $^{18}\text{F}$ ]RO948, and [ $^{18}\text{F}$ ]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2295-2305.	6.4	41
35	Direct Comparison of the Tau PET Tracers $^{18}\text{F}$ -Flortaucipir and $^{18}\text{F}$ -MK-6240 in Human Subjects. <i>Journal of Nuclear Medicine</i> , 2022, 63, 108-116.	5.0	39
36	Staging of Alzheimer's disease: past, present, and future perspectives. <i>Trends in Molecular Medicine</i> , 2022, 28, 726-741.	6.7	36

#	ARTICLE	IF	CITATIONS
37	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 69.	6.2	34
38	Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. <i>EBioMedicine</i> , 2022, 76, 103837.	6.1	34
39	Imaging Alzheimer's disease pathophysiology with PET. <i>Dementia E Neuropsychologia</i> , 2016, 10, 79-90.	0.8	33
40	Association of plasma P-tau181 with memory decline in non-demented adults. <i>Brain Communications</i> , 2021, 3, fcab136.	3.3	33
41	Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 610-617.	3.7	32
42	Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2021, 16, 28.	10.8	32
43	Topographic Distribution of Amyloid- $\beta^2$ , Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease. <i>Neurology</i> , 2021, 96, e81-e92.	1.1	31
44	Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer's disease. <i>Scientific Data</i> , 2015, 2, 150043.	5.3	30
45	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021, 89, 776-785.	1.3	30
46	Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer's disease. <i>Neuropsychopharmacology</i> , 2022, 47, 1128-1136.	5.4	30
47	Cholinergic dysfunction in the dorsal striatum promotes habit formation and maladaptive eating. <i>Journal of Clinical Investigation</i> , 2020, 130, 6616-6630.	8.2	29
48	Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 5989-6001.	7.9	28
49	Impact of the biological definition of Alzheimer's disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?. <i>Translational Neurodegeneration</i> , 2018, 7, 12.	8.0	27
50	Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1021-1030.	6.4	24
51	Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2021, 10, 1.	8.0	23
52	Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2019, 24, 102091.	2.7	21
53	Regional Amyloid- $\beta^2$ Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia. <i>Molecular Neurobiology</i> , 2019, 56, 4916-4924.	4.0	21
54	What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies. <i>Journal of Nuclear Medicine</i> , 2021, 62, 614-619.	5.0	21

#	ARTICLE	IF	CITATIONS
55	Proximity to Parental Symptom Onset and Amyloid- $\beta$ Burden in Sporadic Alzheimer Disease. <i>JAMA Neurology</i> , 2018, 75, 608.	9.0	19
56	Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12154.	3.7	19
57	18F-MK-6240 tau-PET in genetic frontotemporal dementia. <i>Brain</i> , 2022, 145, 1763-1772.	7.6	17
58	Posterior Reversible Encephalopathy Syndrome Following a Scorpion Sting. <i>Journal of Neuroimaging</i> , 2013, 23, 535-536.	2.0	16
59	The prevalence and biomarkers characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 107-113.	3.7	16
60	Posterior Reversible Encephalopathy Syndrome Associated with FOLFOX Chemotherapy. <i>Case Reports in Oncological Medicine</i> , 2013, 2013, 1-3.	0.3	15
61	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. <i>Brain Communications</i> , 2021, 3, fcab073.	3.3	15
62	Interactive rather than independent effect of <i>APOE</i> and sex potentiates tau deposition in women. <i>Brain Communications</i> , 2021, 3, fcab126.	3.3	15
63	Immediate improvement of motor function after epilepsy surgery in congenital hemiparesis. <i>Epilepsia</i> , 2013, 54, e109-11.	5.1	11
64	Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S23-S31.	2.6	11
65	Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.2	11
66	Bilateral perisylvian ulegyria: An under-recognized, surgically remediable epileptic syndrome. <i>Epilepsia</i> , 2013, 54, 1360-1367.	5.1	10
67	Epistasis analysis links immune cascades and cerebral amyloidosis. <i>Journal of Neuroinflammation</i> , 2015, 12, 227.	7.2	10
68	Characterizing biomarker features of cognitively normal individuals with ventriculomegaly. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 12-21.	2.4	9
69	CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem. <i>Neurology: Genetics</i> , 2018, 4, e216.	1.9	8
70	A simplified radiosynthesis of [ <sup>18</sup> F]MK-6240 for tau PET imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 109-114.	1.0	8
71	Preclinical <i>in vivo</i> longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 788-801.	4.3	8
72	Mitochondrial complex I abnormalities underlie neurodegeneration and cognitive decline in Alzheimer's disease. <i>European Journal of Neurology</i> , 2022, 29, 1324-1334.	3.3	8

#	ARTICLE	IF	CITATIONS
73	Topographical distribution of A $\beta$ 2 predicts progression to dementia in A $\beta$ 2 positive mild cognitive impairment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12037.	2.4	7
74	Amyloid $\beta$ -dependent and amyloid $\beta$ -independent effects of Tau in individuals without dementia. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2083-2092.	3.7	7
75	Impact of long- and short-range fibre depletion on the cognitive deficits of fronto-temporal dementia. <i>ELife</i> , 2022, 11, .	6.0	7
76	Rostral-Caudal Hippocampal Functional Convergence Is Reduced Across the Alzheimer $\beta$ ™s Disease Spectrum. <i>Molecular Neurobiology</i> , 2019, 56, 8336-8344.	4.0	6
77	Frontal Variant of Alzheimer Disease Differentiated From Frontotemporal Dementia Using in Vivo Amyloid and Tau Imaging. <i>Cognitive and Behavioral Neurology</i> , 2020, 33, 288-293.	0.9	6
78	Impact of p-tau181 and p-tau217 levels on enrollment for randomized clinical trials and future use of anti-amyloid and anti-tau drugs. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1211-1213.	2.8	5
79	Soluble amyloid-beta isoforms predict downstream Alzheimer $\beta$ ™s disease pathology. <i>Cell and Bioscience</i> , 2021, 11, 204.	4.8	5
80	Suicidal ideation is common in autosomal dominant Alzheimer's disease at $\beta$ -risk persons. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 60-68.	2.7	4
81	Wrappers Feature Selection in Alzheimer's Biomarkers Using kNN and SMOTE Oversampling. <i>TeMa</i> , 2017, 18, 15.	0.1	4
82	Microglial activation and tau propagate jointly across Braak stages. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	4
83	IC $\beta$ 04 $\beta$ 05: IMAGING EPIGENETICS IN THE HUMAN BRAIN WITH THE NOVEL [ <sup>11</sup> C]MARTINOSTAT PET IN PRECLINICAL AD, MCI, AD, AND FRONTOTEMPORAL DEMENTIA INDIVIDUALS. <i>Alzheimer's and Dementia</i> , 2018, 14, P9.	0.8	3
84	IC-P-154: Association between apolipoprotein a-i levels and white matter hyperintensities depends on CSF tau levels in a high-risk cohort of aging cognitively normal persons: The prevent-alzheimer's disease study. , 2015, 11, P103-P103.		2
85	Author Response: Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, <i>APOE</i> $\epsilon$ 4, and Cognitive Impairment. <i>Neurology</i> , 2021, 97, 609-609.	1.1	2
86	[P4 $\beta$ 050]: GRAPH $\beta$ -THEORY ANALYSIS SHOWS A HIGHLY EFFICIENT BUT REDUNDANT NETWORK IN MCI TAU PROPAGATION. <i>Alzheimer's and Dementia</i> , 2017, 13, P1275.	0.8	1
87	O3 $\beta$ 10 $\beta$ 06: BRAIN EPIGENETIC CHANGES MEASURED WITH THE NOVEL [ <sup>11</sup> C]MARTINOSTAT PET MEDIATE THE EFFECTS OF AMYLOID AND TAU PET DEPOSITION ON COGNITION. <i>Alzheimer's and Dementia</i> , 2018, 14, P1045.	0.8	1
88	Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer $\beta$ ™s continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
89	Plasma p $\beta$ -tau181 and p $\beta$ -tau231 offer complementary information to identify Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
90	P3-133: Association between apolipoprotein a-i levels and white matter hyperintensities depends on CSF tau levels in a high-risk cohort of aging cognitively normal persons: The prevent-alzheimer's disease study. , 2015, 11, P674-P675.		0

#	ARTICLE	IF	CITATIONS
91	P4-035: Cerebrospinal fluid ad biomarkers predict poorer cognitive performance in a cognitively intact cohort at risk of Alzheimer's dementia: The prevent-ad program. , 2015, 11, P778-P779.		0
92	P4-097: Should a global or a regional measure of amyloidosis be used in a longitudinal study?. , 2015, 11, P811-P811.		0
93	IC-P-155: Baseline CSF p-tau and fibrillary amyloid load predict mesial temporal hypometabolism in 24-months follow-up in cognitively normal subjects. , 2015, 11, P104-P104.		0
94	O5-01-06: Baseline CSF p-tau and fibrillary amyloid load predict mesial temporal hypometabolism in 24 months' follow-up in cognitively normal subjects. , 2015, 11, P314-P315.		0
95	ICâ€Pâ€027: Amyloidâ€Induced Microglial Activity in Thalamocortical Circuits Predicts Subsequent Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P28.	0.8	0
96	P1â€251: Synergism between Brain Amyloid Accumulation and Neuronal Injury in Corticalâ€Subcortical Circuits Causes Memory Declines in Animal Models. Alzheimer's and Dementia, 2016, 12, P504.	0.8	0
97	ICâ€Pâ€099: Synergism Between Brain Amyloid Accumulation and Neuronal Injury in Corticalâ€Subcortical Circuits Causes Memory Declines in Animal Models. Alzheimer's and Dementia, 2016, 12, P75.	0.8	0
98	IC-P-101: Synergism Between Baseline Amyloidosis and Neuronal Injury as Determinants of Learning Deficits in AD Transgenic Rat Model. , 2016, 12, P77-P77.		0
99	P3â€221: Synergism Between Baseline Amyloidosis and Neuronal Injury as Determinants of Learning Deficits in Alzheimer's Disease Transgenic Rat Model. Alzheimer's and Dementia, 2016, 12, P910.	0.8	0
100	P2-053: Amyloid-Induced Microglial Activity in Thalamocortical Circuits Predicts Subsequent Cognitive Decline. , 2016, 12, P627-P628.		0
101	Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology, 2017, 89, 1931.2-1931.	1.1	0
102	[ICâ€Pâ€017]: VOXELâ€WISE DETERMINATION OF SENSITIVITY, SPECIFICITY, AND THRESHOLDS FOR AMYLOID POSITIVITY USING [ <sup>18</sup> F]FLORBETAPIR PET. Alzheimer's and Dementia, 2017, 13, P20.	0.8	0
103	[ICâ€Pâ€034]: GRAPHâ€THEORY ANALYSIS SHOWS A HIGHLY EFFICIENT BUT REDUNDANT NETWORK IN MCI TAU PROPAGATION. Alzheimer's and Dementia, 2017, 13, P30.	0.8	0
104	O3â€01â€04: CORRELATION BETWEEN CSF Tâ€TAU AND Pâ€TAU WITH [ <sup>18</sup> F]MK6240 IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1009.	0.8	0
105	P3â€338: AMYLOID AND MICROGLIAL ACTIVATION SYNERGY LEADS TO HYPOMETABOLISM IN AD BRAIN: MICROPET LONGITUDINAL STUDY. Alzheimer's and Dementia, 2018, 14, P1211.	0.8	0
106	P1â€482: ASSOCIATION OF [ <sup>18</sup> F]MK6240 PET TAU BINDING WITH CLINICAL DIAGNOSIS, APOE4, COGNITION, AMYLOID, AGE, AND BRAAK STAGES ACROSS THE AD CLINICAL SPECTRUM. Alzheimer's and Dementia, 2018, 14, P510.	0.8	0
107	P2â€462: UNBIASED ASSESSMENT OF GLOBAL AMYLOID LOAD AS DETERMINED BY VOXELâ€WISE RECEIVER OPERATING CHARACTERISTIC ANALYSIS. Alzheimer's and Dementia, 2018, 14, P898.	0.8	0
108	ICâ€Pâ€022: LATERAL TEMPORAL AMYLOID LOAD PREDICTS PROGRESSION TO ALZHEIMER'S DEMENTIA. Alzheimer's and Dementia, 2018, 14, P28.	0.8	0

#	ARTICLE	IF	CITATIONS
109	P2â€Pâ€03: COGNITIVE PERFORMANCE FOR VERBAL MEMORY AND SEMANTIC VERBAL FLUENCY AS A FUNCTION OF TAU PROTEIN LEVELS. Alzheimer's and Dementia, 2018, 14, P923.	0.8	0
110	ICâ€Pâ€055: REGIONAL PATTERNS OF TAU DEPOSITION DRIVEN BY LOCAL AMYLOID ACCUMULATION RECAPITULATE BRAAK STAGES IN AD. Alzheimer's and Dementia, 2018, 14, P52.	0.8	0
111	ICâ€Pâ€023: UNBIASED ASSESSMENT OF GLOBAL AMYLOID LOAD AS DETERMINED BY VOXELâ€WISE RECEIVER OPERATING CHARACTERISTIC ANALYSIS. Alzheimer's and Dementia, 2018, 14, P29.	0.8	0
112	P2â€353: THE IMPACT OF TSPO RS6971 POLYMORPHISM IN A CANADIAN NEUROIMAGING STUDY OF NEUROINFLAMMATION. Alzheimer's and Dementia, 2018, 14, P823.	0.8	0
113	P1â€148: THE EFFECT OF PROTON PUMP INHIBITORS AND <i>CYP2C19</i> ON AMYLOID PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P333.	0.8	0
114	ICâ€Pâ€063: THE EFFECT OF PROTON PUMP INHIBITORS AND CYP2C19 ON AMYLOID PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P58.	0.8	0
115	ICâ€Pâ€064: THE IMPACT OF TSPO RS6971 POLYMORPHISM IN A CANADIAN NEUROIMAGING STUDY OF NEUROINFLAMMATION. Alzheimer's and Dementia, 2018, 14, P58.	0.8	0
116	P1â€342: SUICIDAL IDEATION IS PREVALENT IN BOTH ASYMPTOMATIC AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE MUTATION AND NONâ€MUTATION CARRIERS. Alzheimer's and Dementia, 2018, 14, P424.	0.8	0
117	ICâ€Pâ€213: [ <sup>18</sup> F]MK6240 PET TAU BINDING IN ATYPICAL AD AND NONâ€AD TAUOPATHIES. Alzheimer's and Dementia, 2018, 14, P174.	0.8	0
118	ICâ€Pâ€208: CORRELATION BETWEEN CSF Tâ€TAU AND Pâ€TAU WITH [ <sup>18</sup> F]MK6240 IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P171.	0.8	0
119	P3â€441: LOGICAL MEMORY DEFICITS ACROSS ALZHEIMER'S DISEASE SPECTRUM ARE ASSOCIATED WITH PATTERNS OF A TAU PROPAGATION PREDICTED BY BRAAK STAGING. Alzheimer's and Dementia, 2018, 14, P1283.	0.8	0
120	ICâ€Pâ€103: LOGICAL MEMORY DEFICITS ACROSS ALZHEIMER'S DISEASE SPECTRUM ARE ASSOCIATED WITH PATTERNS OF TAU PROPAGATION PREDICTED BY BRAAK STAGING. Alzheimer's and Dementia, 2018, 14, P89.	0.8	0
121	ICâ€Pâ€054: AMYLOID AND MICROGLIAL ACTIVATION SYNERGY LEADS TO HYPOMETABOLISM IN THE AD BRAIN: MICROPET LONGITUDINAL STUDY. Alzheimer's and Dementia, 2018, 14, P51.	0.8	0
122	P4â€107: REGIONAL PATTERNS OF TAU DEPOSITION DRIVEN BY LOCAL AMYLOID ACCUMULATION RECAPITULATE BRAAK STAGES IN AD. Alzheimer's and Dementia, 2018, 14, P1479.	0.8	0
123	P1â€486: LATERAL TEMPORAL AMYLOID LOAD PREDICTS THE PROGRESSION TO ALZHEIMER'S DEMENTIA. Alzheimer's and Dementia, 2018, 14, P513.	0.8	0
124	ICâ€Pâ€168: ISSUES REGARDING [ <sup>18</sup> F]MK6240 REFERENCE REGION SELECTION BASED ON THE FULL KINETIC MODELING. Alzheimer's and Dementia, 2019, 15, P132.	0.8	0
125	ICâ€Pâ€180: PREDICTING TAU PATHOLOGY PROGRESSION IN ALZHEIMER'S DISEASE BY MATHEMATICAL SIMULATION: FURTHER RESULTS AND PRIORITIZATION OF MODIFICATIONS FOR FURTHER IMPROVEMENTS. Alzheimer's and Dementia, 2019, 15, P141.	0.8	0
126	ICâ€Pâ€132: CORTICAL IRON DEPOSITION IN ALZHEIMER'S DISEASE CONTRASTS WITH AGEâ€RELATED SUBCORTICAL DEPOSITION. Alzheimer's and Dementia, 2019, 15, P108.	0.8	0



#	ARTICLE	IF	CITATIONS
127	Elderly Man Repeating Questions about Upcoming Appointments. , 2021, , 14-17.		0
128	Clinical Meaningfulness of Biomarker Endpoints in Alzheimer's Disease Research. Neuromethods, 2018, , 235-248.	0.3	0
129	Associations between neutrophils and amyloid deposition in the Alzheimer's disease spectrum. Alzheimer's and Dementia, 2021, 17, .	0.8	0
130	Association of tau pathology and vascular risk factor burden with longitudinal measures of plasma neurofilament light. Alzheimer's and Dementia, 2021, 17, .	0.8	0
131	Verbal fluency associated with tau accumulation and not amyloid deposition in the Alzheimer's disease spectrum. Alzheimer's and Dementia, 2021, 17, .	0.8	0
132	Profiling tau accumulation with SPReAD: Sub-stages for propagation regions in Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e054239.	0.8	0